Cancer diagnostics company, Pacific Edge, has reported resilient demand for its tests in the three months to the end of June 2025, despite the loss of Medicare coverage in April 2025 and the disruption caused by the transition of US customers from Detect to Triage.
The company said Cxbladder Triage represented around 77% of its US total laboratory throughput in June 2025, up from 22% in the previous quarter.
However, US total laboratory throughput in Q1 2026 was down 11.9% to 5,717 tests.
The company also reported positive discussions with Medicare Administrative Contractor Novitas, following the lodging of a Medicare reconsideration request based on new evidence.
See more
